Approximately 20 million adults in the U.S. have diabetes, and people with diabetes have twice the risk of contracting hepatitis B compared to those without the disease1. Spread through contact with infected blood and bodily fluids, the hepatitis B virus attacks the liver slowly and stealthily with little or no symptoms. Most people don’t know they are infected until decades later when warning signs first appear. In fact, the hepatitis B virus is the leading cause of cirrhosis and liver cancer globally. 2
Vaccines: Essential Protection for You and Your Loved Ones
The COVID-19 health crisis has been an important reminder of the power of vaccines to protect us and our families from potential serious illness resulting from life-threatening viruses.
Safe and effective vaccines have been proven to work as the front-line of defense against hepatitis B infection for four decades. That’s why the Centers for Disease Control and Prevention (CDC) – aiming to eliminate hepatitis B among people with diabetes – recommends hepatitis B vaccination for adults aged 19 to 59 with diabetes as soon as possible after their diagnosis. For people aged 60 and older with diabetes, CDC recommends vaccination at physician’s discretion.
HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]: The Only Hepatitis B Vaccine that Protects In One Month with Only 2-doses
Historically, hepatitis B vaccine choices have been limited to a three-dose series given over six months. Recent innovation in vaccine development has brought forward a two-dose HBV vaccine option that is scientifically proven to be safe and effective in people living with diabetes.
HEPLISAV-B provides protection against hepatitis B in the fastest way available. In a head-to-head clinical trial, HEPLISAV-B was proven to be 90% effective for people with diabetes in protecting against HBV; compared to Engerix-B, a three-dose vaccine series given over six months, which only protected 65.1% of patients. As the only two-dose hepatitis B vaccine for adults, HEPLISAV-B also offers unmatched speed-to-protection, enabling you to complete the full vaccine series in just one month.
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. Please see Important Safety Information below.
Get Protected Against Hepatitis B: Talk to Your Pharmacist
Take an important step toward a healthier future by making sure you are vaccinated against hepatitis B. As a person with diabetes, you are at a higher risk of vaccines not working effectively. Ask your pharmacist today about gaining the optimal protection you need with HEPLISAV-B.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
For full Prescribing Information for HEPLISAV-B, click here.
2Hepatitis B Foundation. https://www.hepb.org/research-and-programs/liver/risk-factors-for-liver-cancer/